Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: Pre-market Movers » 08:56
12/06/22
12/06
08:56
12/06/22
08:56
VVNT

Vivint Smart Home

$8.98 /

-0.44 (-4.67%)

, JPM

JPMorgan

$131.31 /

-3.88 (-2.87%)

, GE

General Electric

$84.67 /

-2.135 (-2.46%)

, SIG

Signet Jewelers

$57.78 /

-3.71 (-6.03%)

, JILL

J.Jill

$24.00 /

-1 (-4.00%)

, GTLB

GitLab

$38.35 /

-2.92 (-7.08%)

, RCL

Royal Caribbean

$59.44 /

-1.07 (-1.77%)

, BIVI

BioVie

$5.18 /

-0.275 (-5.04%)

, MRTX

Mirati Therapeutics

$92.78 /

-3.05 (-3.18%)

, HLF

Herbalife Nutrition

$17.46 /

-0.225 (-1.27%)

, MEIP

MEI Pharma

/

+

, NRG

NRG Energy

$40.84 /

-0.415 (-1.01%)

Check out this morning's…

ShowHide Related Items >><<
VVNT Vivint Smart Home
$8.98 /

-0.44 (-4.67%)

SIG Signet Jewelers
$57.78 /

-3.71 (-6.03%)

RCL Royal Caribbean
$59.44 /

-1.07 (-1.77%)

NRG NRG Energy
$40.84 /

-0.415 (-1.01%)

MRTX Mirati Therapeutics
$92.78 /

-3.05 (-3.18%)

MEIP MEI Pharma
/

+

JPM JPMorgan
$131.31 /

-3.88 (-2.87%)

JILL J.Jill
$24.00 /

-1 (-4.00%)

HLF Herbalife Nutrition
$17.46 /

-0.225 (-1.27%)

GTLB GitLab
$38.35 /

-2.92 (-7.08%)

GE General Electric
$84.67 /

-2.135 (-2.46%)

BIVI BioVie
$5.18 /

-0.275 (-5.04%)

VVNT Vivint Smart Home
$8.98 /

-0.44 (-4.67%)

11/03/22 Maxim
Alarm.com price target lowered to $80 from $90 at Maxim
10/17/22 Morgan Stanley
Vivint Smart Home price target lowered to $7.30 from $7.50 at Morgan Stanley
06/28/22 Evercore ISI
Vivint Smart Home price target lowered to $6 from $8 at Evercore ISI
06/13/22 JPMorgan
Vivint Smart Home price target lowered to $10 from $11 at JPMorgan
JPM JPMorgan
$131.31 /

-3.88 (-2.87%)

12/06/22 Morgan Stanley
JPMorgan upgraded to Overweight from Underweight at Morgan Stanley
10/17/22 Citi
JPMorgan shares offer 'excellent entry point,' says Citi
10/17/22 BMO Capital
JPMorgan price target raised to $158 from $149 at BMO Capital
10/05/22 Morgan Stanley
JPMorgan price target lowered to $126 from $127 at Morgan Stanley
GE General Electric
$84.67 /

-2.135 (-2.46%)

12/06/22 Oppenheimer
General Electric upgraded to Outperform from Perform at Oppenheimer
12/05/22 Deutsche Bank
General Electric price target raised to $94 from $89 at Deutsche Bank
11/22/22 Northland
Hyliion Holdings initiated with an Outperform at Northland
11/11/22 UBS
General Electric price target raised to $98 from $79 at UBS
SIG Signet Jewelers
$57.78 /

-3.71 (-6.03%)

12/02/22 Citi
Citi opens '30 day negative Catalyst Watch' on Signet Jewelers ahead of earnings
08/10/22 Citi
Signet Jewelers price target lowered to $65 from $76 at Citi
06/10/22 UBS
Signet Jewelers price target lowered to $120 from $138 at UBS
06/10/22 Citi
Signet Jewelers price target lowered to $76 from $94 at Citi
JILL J.Jill
$24.00 /

-1 (-4.00%)

GTLB GitLab
$38.35 /

-2.92 (-7.08%)

12/06/22 Piper Sandler
GitLab price target lowered to $60 from $67 at Piper Sandler
11/29/22 BofA
BofA ups GitLab target to $78 with survey suggesting Q3 beat
11/28/22 RBC Capital
GitLab price target lowered to $55 from $75 at RBC Capital
11/28/22 Piper Sandler
GitLab remains a top idea with $67 target at Piper Sandler
RCL Royal Caribbean
$59.44 /

-1.07 (-1.77%)

12/06/22 JPMorgan
Royal Caribbean assumed with Underweight from Overweight at JPMorgan
11/22/22 Truist
Royal Caribbean price target raised to $62 from $58 at Truist
11/17/22 Credit Suisse
Norwegian Cruise downgraded to Underperform from Outperform at Credit Suisse
11/14/22 UBS
Royal Caribbean price target raised to $76 from $56 at UBS
BIVI BioVie
$5.18 /

-0.275 (-5.04%)

07/22/22 Cantor Fitzgerald
BioVie initiated with an Overweight at Cantor Fitzgerald
03/14/22 Oppenheimer
BioVie initiated with an Outperform at Oppenheimer
01/24/22 B. Riley
BioVie price target lowered to $18 from $27 at B. Riley
MRTX Mirati Therapeutics
$92.78 /

-3.05 (-3.18%)

12/02/22 Piper Sandler
Mirati trial continuation 'tilts the scale for a positive outcome,' says Piper
11/22/22 BMO Capital
BMO says Mirati could be valued at up to $200 per share in 'upside scenario'
11/16/22 Citi
Mirati Therapeutics price target lowered to $121 from $127 at Citi
10/28/22 B. Riley
Mirati Therapeutics initiated with a Neutral at B. Riley
HLF Herbalife Nutrition
$17.46 /

-0.225 (-1.27%)

11/01/22 B. Riley
Herbalife Nutrition price target lowered to $31 from $38 at B. Riley
11/01/22 Citi
Herbalife Nutrition price target lowered to $26 from $30 at Citi
10/05/22 Citi
Herbalife Nutrition price target lowered to $30 from $36 at Citi
08/03/22 B. Riley
Herbalife Nutrition price target lowered to $38 from $41 at B. Riley
MEIP MEI Pharma
/

+

12/06/22 Truist
MEI Pharma cut to Hold at Truist after decision to discontinue zandelisib
12/06/22 BTIG
MEI Pharma downgraded to Neutral from Buy at BTIG
12/06/22 Truist
MEI Pharma downgraded to Hold from Buy at Truist
04/20/22 Alliance Global Partners
MEI Pharma price target lowered to $5 from $9 at Alliance Global Partners
NRG NRG Energy
$40.84 /

-0.415 (-1.01%)

06/07/22 BofA
NRG Energy downgraded to Underperform from Neutral at BofA
04/21/22 BofA
NRG Energy downgraded to Neutral from Buy at BofA
01/05/22 UBS
NRG Energy downgraded to Neutral from Buy at UBS
01/05/22 UBS
NRG Energy downgraded to Neutral from Buy at UBS
VVNT Vivint Smart Home
$8.98 /

-0.44 (-4.67%)

SIG Signet Jewelers
$57.78 /

-3.71 (-6.03%)

RCL Royal Caribbean
$59.44 /

-1.07 (-1.77%)

NRG NRG Energy
$40.84 /

-0.415 (-1.01%)

MRTX Mirati Therapeutics
$92.78 /

-3.05 (-3.18%)

MEIP MEI Pharma
/

+

JPM JPMorgan
$131.31 /

-3.88 (-2.87%)

JILL J.Jill
$24.00 /

-1 (-4.00%)

HLF Herbalife Nutrition
$17.46 /

-0.225 (-1.27%)

GTLB GitLab
$38.35 /

-2.92 (-7.08%)

GE General Electric
$84.67 /

-2.135 (-2.46%)

RCL Royal Caribbean
$59.44 /

-1.07 (-1.77%)

NRG NRG Energy
$40.84 /

-0.415 (-1.01%)

MRTX Mirati Therapeutics
$92.78 /

-3.05 (-3.18%)

JPM JPMorgan
$131.31 /

-3.88 (-2.87%)

GE General Electric
$84.67 /

-2.135 (-2.46%)

SIG Signet Jewelers
$57.78 /

-3.71 (-6.03%)

RCL Royal Caribbean
$59.44 /

-1.07 (-1.77%)

MRTX Mirati Therapeutics
$92.78 /

-3.05 (-3.18%)

JPM JPMorgan
$131.31 /

-3.88 (-2.87%)

HLF Herbalife Nutrition
$17.46 /

-0.225 (-1.27%)

GTLB GitLab
$38.35 /

-2.92 (-7.08%)

GE General Electric
$84.67 /

-2.135 (-2.46%)

BIVI BioVie
$5.18 /

-0.275 (-5.04%)

SIG Signet Jewelers
$57.78 /

-3.71 (-6.03%)

RCL Royal Caribbean
$59.44 /

-1.07 (-1.77%)

JPM JPMorgan
$131.31 /

-3.88 (-2.87%)

HLF Herbalife Nutrition
$17.46 /

-0.225 (-1.27%)

GTLB GitLab
$38.35 /

-2.92 (-7.08%)

GE General Electric
$84.67 /

-2.135 (-2.46%)

Downgrade
MEI Pharma cut to Hold at Truist after decision to discontinue zandelisib » 08:08
12/06/22
12/06
08:08
12/06/22
08:08
MEIP

MEI Pharma

/

+

Truist analyst Robyn…

Truist analyst Robyn Karnauskas downgraded MEI Pharma to Hold from Buy. The analyst cites the company's decision to discontinue the development of its lead drug Zandelisib based on the feedback from the FDA meeting, along with its announcement of a 30% workforce reduction.

ShowHide Related Items >><<
MEIP MEI Pharma
/

+

MEIP MEI Pharma
/

+

12/06/22 BTIG
MEI Pharma downgraded to Neutral from Buy at BTIG
12/06/22 Truist
MEI Pharma downgraded to Hold from Buy at Truist
04/20/22 Alliance Global Partners
MEI Pharma price target lowered to $5 from $9 at Alliance Global Partners
03/25/22 BTIG
MEI Pharma price target lowered to $4 from $11 at BTIG
MEIP MEI Pharma
/

+

Downgrade
MEI Pharma downgraded to Neutral from Buy at BTIG » 05:19
12/06/22
12/06
05:19
12/06/22
05:19
MEIP

MEI Pharma

/

+

BTIG analyst Justin Zelin…

BTIG analyst Justin Zelin downgraded MEI Pharma to Neutral from Buy without a price target. The company announced plans to initiate strategic realignment of its portfolio following feedback with partner Kyowa Kirin from the FDA at a late November Meeting, where the parties will discontinue global development of Zandelisib, Zelin tells investors in a research note. The analyst downgrades MEI saying the primary valuation driver was future revenues from Zandelisib. He now awaits further clinical updates from the company's early-stage pipeline assets next year.

ShowHide Related Items >><<
MEIP MEI Pharma
/

+

MEIP MEI Pharma
/

+

12/06/22 Truist
MEI Pharma downgraded to Hold from Buy at Truist
04/20/22 Alliance Global Partners
MEI Pharma price target lowered to $5 from $9 at Alliance Global Partners
03/25/22 BTIG
MEI Pharma price target lowered to $4 from $11 at BTIG
03/25/22 Jefferies
Jefferies cuts MEI Pharma to Hold on shift in FDA's thinking on PI3K inhibitors
MEIP MEI Pharma
/

+

Downgrade
MEI Pharma downgraded to Hold from Buy at Truist » 05:16
12/06/22
12/06
05:16
12/06/22
05:16
MEIP

MEI Pharma

/

+

Truist analyst Robyn…

Truist analyst Robyn Karnauskas downgraded MEI Pharma to Hold from Buy.

ShowHide Related Items >><<
MEIP MEI Pharma
/

+

MEIP MEI Pharma
/

+

04/20/22 Alliance Global Partners
MEI Pharma price target lowered to $5 from $9 at Alliance Global Partners
03/25/22 BTIG
MEI Pharma price target lowered to $4 from $11 at BTIG
03/25/22 Jefferies
Jefferies cuts MEI Pharma to Hold on shift in FDA's thinking on PI3K inhibitors
03/25/22 Truist
MEI Pharma price target lowered to $3 from $8 at Truist
MEIP MEI Pharma
/

+

Hot Stocks
MEI Pharma announces 30% workforce reduction » 17:14
12/05/22
12/05
17:14
12/05/22
17:14
MEIP

MEI Pharma

/

+

MEIP plans to streamline…

MEIP plans to streamline its organization towards the continued clinical development of voruciclib and ME-344. As a result, it plans to initiate a staggered workforce reduction, initially representing approximately 30% of the current workforce in connection with the wind down of the zandelisib development program outside of Japan, which costs are shared with Kyowa Kirin, our global development partner. Following completion of the zandelisib wind down and associated workforce reductions, MEI expects that, along with any additional workforce reductions to be determined to fully align resources going forward, its existing cash, cash equivalents and marketable securities will be sufficient to fund operations through clinical data milestones for both voruciclib and ME-344.

ShowHide Related Items >><<
MEIP MEI Pharma
/

+

MEIP MEI Pharma
/

+

04/20/22 Alliance Global Partners
MEI Pharma price target lowered to $5 from $9 at Alliance Global Partners
03/25/22 BTIG
MEI Pharma price target lowered to $4 from $11 at BTIG
03/25/22 Jefferies
Jefferies cuts MEI Pharma to Hold on shift in FDA's thinking on PI3K inhibitors
03/25/22 Truist
MEI Pharma price target lowered to $3 from $8 at Truist
MEIP MEI Pharma
/

+

Hot Stocks
MEI Pharma announces realignment of clinical development efforts » 17:06
12/05/22
12/05
17:06
12/05/22
17:06
MEIP

MEI Pharma

/

+

MEI Pharma announced that…

MEI Pharma announced that it plans to initiate a realignment of its clinical development efforts following the discontinuation of global development outside Japan of its PI3K delta inhibitor, zandelisib. As part of the realignment, the company plans to streamline its organization towards the development of two earlier clinical-stage assets, voruciclib and ME-344. Following completion of the workforce reductions, MEI expects its existing cash, cash equivalents and marketable securities will be sufficient to fund operations through clinical data milestones for both voruciclib and ME-344. The company further announced that it has engaged Torreya Partners as financial advisor to help explore additional strategic opportunities.

ShowHide Related Items >><<
MEIP MEI Pharma
/

+

MEIP MEI Pharma
/

+

04/20/22 Alliance Global Partners
MEI Pharma price target lowered to $5 from $9 at Alliance Global Partners
03/25/22 BTIG
MEI Pharma price target lowered to $4 from $11 at BTIG
03/25/22 Jefferies
Jefferies cuts MEI Pharma to Hold on shift in FDA's thinking on PI3K inhibitors
03/25/22 Truist
MEI Pharma price target lowered to $3 from $8 at Truist
MEIP MEI Pharma
/

+

Hot Stocks
MEI Pharma, Kyowa Kirin to discontinue zandelisib development outside Japan » 17:02
12/05/22
12/05
17:02
12/05/22
17:02
MEIP

MEI Pharma

/

+

MEI Pharma and Kyowa…

MEI Pharma and Kyowa Kirin Co. announced that after receiving the most recent guidance from a late November meeting with the U.S. FDA, the companies are discontinuing global development of zandelisib outside of Japan for B-cell malignancies. Kyowa Kirin is continuing the ongoing clinical trials including Phase 2 MIRAGE study evaluating Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphomas and will explore the potential for a submission to Japanese health authorities based on data from the MIRAGE and TIDAL clinical trials.

ShowHide Related Items >><<
MEIP MEI Pharma
/

+

MEIP MEI Pharma
/

+

04/20/22 Alliance Global Partners
MEI Pharma price target lowered to $5 from $9 at Alliance Global Partners
03/25/22 BTIG
MEI Pharma price target lowered to $4 from $11 at BTIG
03/25/22 Jefferies
Jefferies cuts MEI Pharma to Hold on shift in FDA's thinking on PI3K inhibitors
03/25/22 Truist
MEI Pharma price target lowered to $3 from $8 at Truist
MEIP MEI Pharma
/

+

Hot Stocks
Kyowa Kirin, MEI Pharma announce topline data from MIRAGE study » 08:12
11/18/22
11/18
08:12
11/18/22
08:12
MEIP

MEI Pharma

/

+

Kyowa Kirin and MEI…

Kyowa Kirin and MEI Pharma announced topline data from the Phase 2 MIRAGE study evaluating zandelisib, an orally administered investigational phosphatidylinositol 3-kinase delta inhibitor, in patients with indolent B-cell Non-Hodgkin's Lymphoma, or iB-NHL, without small lymphocytic lymphoma, or SLL, lymphoplasmacytic lymphoma, or LPL, and Waldenstrom's macroglobulinemia, or WM, in Japan. The data demonstrated a 75.4% objective response rate, or ORR, and 24.6% of patients achieved a complete response, or CR, as determined by Independent Review Committee assessment. The data is currently insufficiently mature to accurately estimate duration of response. With 9.5 months median duration of follow-up, a discontinuation rate due to any treatment emergent adverse event was 14.8%. The MIRAGE study is a multicenter, open-label, single-arm Phase 2 trial evaluating zandelisib as monotherapy for Japanese patients with relapsed or refractory iB-NHL who received at least two prior systemic therapies. A total of 61 patients were enrolled and the median age of patients was 70 years old. Enrolled patients were generally heavily pretreated; the median number of prior therapies was 3. The primary efficacy endpoint is ORR as assessed by IRRC using a modified Lugano criteria. Patients were administered zandelisib 60 mg once daily for two 28-day cycles as response induction therapy, followed thereafter by 60 mg once daily dosing for the first seven days of each subsequent 28-day cycle, a schedule called Intermittent Dosing Therapy. The primary endpoint of ORR of zandelisib as a single agent was 75.4%, as assessed by IRRC; the complete response rate was 24.6%. As of the data cutoff date, the data are not sufficiently mature to accurately estimate the final DOR. With a median follow-up of 9.5 months, 14.8% of patients discontinued therapy due to any treatment emergent adverse event. Grade 3 adverse events of special interest were AST and ALT elevation in 8.2% of patients, rash in 3.3%, and 1.6% each for diarrhea, colitis and lung infection. We also recently announced the publication of data from the Phase 1 study of zandelisib in Japanese patients with r/r iB-NHL in the International Journal of Hematology. The publication, entitled "Zandelisib in Japanese patients with relapsed or refractory indolent non-Hodgkin's lymphoma: an open-label, multicenter, dose-escalation phase 1 study" is available on the journal website. The publication reported a 100% ORR and that 22.2% of patients achieved CR starting on a continuous daily schedule; patients could be switched to intermittent dosing for an adverse event. No dose-limiting toxicities were observed in the first cycle of therapy, and the maximum tolerated dose was not reached. With 17.5 months median duration of follow-up, zandelisib was generally well tolerated at 60 mg resulting in the recommended phase 2 dose in Japanese patients.

ShowHide Related Items >><<
MEIP MEI Pharma
/

+

MEIP MEI Pharma
/

+

04/20/22 Alliance Global Partners
MEI Pharma price target lowered to $5 from $9 at Alliance Global Partners
03/25/22 BTIG
MEI Pharma price target lowered to $4 from $11 at BTIG
03/25/22 Jefferies
Jefferies cuts MEI Pharma to Hold on shift in FDA's thinking on PI3K inhibitors
03/25/22 Truist
MEI Pharma price target lowered to $3 from $8 at Truist
MEIP MEI Pharma
/

+

  • 02
    Dec
Earnings
MEI Pharma reports Q1 EPS (12c), consensus (14c) » 16:13
11/14/22
11/14
16:13
11/14/22
16:13
MEIP

MEI Pharma

/

+

Reports Q1 revenue…

Reports Q1 revenue $8.73M, consensus $5.9M. "As we move through fiscal year 2023 and continue to assess FDA concerns regarding the risk benefit analysis of marketed PI3Kdelta inhibitors to treat indolent lymphomas, as well as the impact of these concerns and other global factors on our Phase 3 COASTAL study, we also look forward to reporting advances across our clinical development pipeline. This includes reporting updated data from multiple zandelisib studies at the ASH annual meeting in December, and also reporting advances in our other development programs, including initiation of a trial evaluating voruciclib's potential to synergize with venetoclax in patients with AML, and a trial evaluating the combination of ME-344 plus bevacizumab in patients with relapsed and refractory colorectal cancer," said Daniel P. Gold, Ph.D., president and chief executive officer of MEI Pharma. "We remain well capitalized with $138 million to advance our pipeline and continue operations for approximately two years."

ShowHide Related Items >><<
MEIP MEI Pharma
/

+

MEIP MEI Pharma
/

+

04/20/22 Alliance Global Partners
MEI Pharma price target lowered to $5 from $9 at Alliance Global Partners
03/25/22 BTIG
MEI Pharma price target lowered to $4 from $11 at BTIG
03/25/22 Jefferies
Jefferies cuts MEI Pharma to Hold on shift in FDA's thinking on PI3K inhibitors
03/25/22 Truist
MEI Pharma price target lowered to $3 from $8 at Truist
MEIP MEI Pharma
/

+

  • 02
    Dec
Over a quarter ago
Earnings
MEI Pharma reports FY22 EPS (50c), consensus (51c) » 16:06
09/08/22
09/08
16:06
09/08/22
16:06
MEIP

MEI Pharma

/

+

Reports FY22 revenue…

Reports FY22 revenue $40.7M, consensus $46.38M. "This past fiscal year was marked by progress on multiple fronts, including the first patient dosed in our Phase 3 COASTAL study, strong zandelisib data reported from the global Phase 2 TIDAL study, reporting of data from our voruciclib and ME-344 programs, and key appointments to our executive team and board of directors," said Daniel P. Gold, Ph.D., president and chief executive officer of MEI Pharma. "Further, we remain well capitalized with $153 million to advance our pipeline and continue operations for about two years."

ShowHide Related Items >><<
MEIP MEI Pharma
/

+

MEIP MEI Pharma
/

+

04/20/22 Alliance Global Partners
MEI Pharma price target lowered to $5 from $9 at Alliance Global Partners
03/25/22 BTIG
MEI Pharma price target lowered to $4 from $11 at BTIG
03/25/22 Jefferies
Jefferies cuts MEI Pharma to Hold on shift in FDA's thinking on PI3K inhibitors
03/25/22 Truist
MEI Pharma price target lowered to $3 from $8 at Truist
MEIP MEI Pharma
/

+

  • 02
    Dec
MEIP MEI Pharma
/

+

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.